Avalo Therapeutics, Inc. (AVTX) Balance Sheet

The consistent contraction in total assets suggests that the company is liquidating its resource base to fund ongoing R&D operations. Investors should monitor whether this trajectory forces a pivot toward further asset divestitures or increasingly dilutive equity financing to maintain operational continuity.

While the current ratio of 7.66 appears superficially robust, it is largely a function of the company's limited short-term liabilities rather than operational liquidity. The lack of recurring revenue means this cash buffer is essentially a finite runway that necessitates constant capital market access.

The persistent negative retained earnings indicate that the company has yet to achieve a return on its invested capital, placing the entire burden of value creation on future clinical trial outcomes. This structure suggests that existing shareholders face a high risk of continued dilution as management seeks to bridge the funding gap.